News

News 31.10.2019 Zurich-Schlieren, October 31, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, announced today its Interim Management Statement for the period ending September 30, 2019. “Abicipar represents the first DARPin® therapeutic to be accepted for review by FDA...

Internal events
Event date: 05.11.2019 Prof. Dr. Dr. Vera Regitz-Zagrosek Charite, Berlin, DE Sex, gender and drug development 5th of November 2019 at 4 pm Wagistr. 12 seminar room 4th floor Drugs may act differently in women and men. Biological differences between women and men may be caused by sex specific gene expression, by sex specific epigenetic modifications and by...

News 22.10.2019 Zurich, Switzerland – October 22, 2019 – Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich. In...

News 20.10.2019 Schlieren, Switzerland – October 16, 2019 – AL-S Pharma AG, a biotech company jointly founded and financed by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter Phase 1 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis (ALS). AP-101 is...

News 20.10.2019 DUBLIN, IRELAND – OCTOBER 11, 2019 – Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced two-year data from the CEDAR...